Cargando…

In silico, in vitro and cellular analysis with a kinome-wide inhibitor panel correlates cellular LRRK2 dephosphorylation to inhibitor activity on LRRK2

Leucine-rich repeat kinase 2 (LRRK2) is a complex, multidomain protein which is considered a valuable target for potential disease-modifying therapeutic strategies for Parkinson's disease (PD). In mammalian cells and brain, LRRK2 is phosphorylated and treatment of cells with inhibitors of LRRK2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vancraenenbroeck, Renée, De Raeymaecker, Joren, Lobbestael, Evy, Gao, Fangye, De Maeyer, Marc, Voet, Arnout, Baekelandt, Veerle, Taymans, Jean-Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042160/ https://www.ncbi.nlm.nih.gov/pubmed/24917786 http://dx.doi.org/10.3389/fnmol.2014.00051

Ejemplares similares

LRRK2 Kinase Activity Is Dependent on LRRK2 GTP Binding Capacity but Independent of LRRK2 GTP Binding
por: Taymans, Jean-Marc, et al.
Publicado: (2011)

Pathogenic LRRK2 requires secondary factors to induce cellular toxicity
por: Lobbestael, Evy, et al.
Publicado: (2020)

Multiple-Hit Hypothesis in Parkinson’s Disease: LRRK2 and Inflammation
por: Cabezudo, Diego, et al.
Publicado: (2020)

Cryo-EM analysis of homodimeric full-length LRRK2 and LRRK1 protein complexes
por: Sejwal, Kushal, et al.
Publicado: (2017)

Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation
por: Lobbestael, E., et al.
Publicado: (2016)

Phosphatases of α-synuclein, LRRK2, and tau: important players in the phosphorylation-dependent pathology of Parkinsonism
por: Taymans, Jean-Marc, et al.
Publicado: (2014)

Inhibition of LRRK2 or Casein Kinase 1 Results in LRRK2 Protein Destabilization
por: De Wit, T., et al.
Publicado: (2018)

Biochemical Characterization of Highly Purified Leucine-Rich Repeat Kinases 1 and 2 Demonstrates Formation of Homodimers
por: Civiero, Laura, et al.
Publicado: (2012)

Divergent Effects of G2019S and R1441C LRRK2 Mutations on LRRK2 and Rab10 Phosphorylations in Mouse Tissues
por: Iannotta, Lucia, et al.
Publicado: (2020)

PAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2
por: Civiero, Laura, et al.
Publicado: (2017)

RAB7L1-Mediated Relocalization of LRRK2 to the Golgi Complex Causes Centrosomal Deficits via RAB8A
por: Madero-Pérez, Jesús, et al.
Publicado: (2018)

LRRK2 dephosphorylation increases its ubiquitination
por: Zhao, Jing, et al.
Publicado: (2015)

GTP binding regulates cellular localization of Parkinson's disease-associated LRRK2
por: Blanca Ramírez, Marian, et al.
Publicado: (2017)

LRRK2 Phosphorylation, More Than an Epiphenomenon
por: Marchand, Antoine, et al.
Publicado: (2020)

Parkinson disease-associated mutations in LRRK2 cause centrosomal defects via Rab8a phosphorylation
por: Madero-Pérez, Jesús, et al.
Publicado: (2018)

Screening for Novel LRRK2 Inhibitors Using a High-Throughput TR-FRET Cellular Assay for LRRK2 Ser935 Phosphorylation
por: Hermanson, Spencer B., et al.
Publicado: (2012)

A Phosphosite Mutant Approach on LRRK2 Links Phosphorylation and Dephosphorylation to Protective and Deleterious Markers, Respectively
por: Marchand, Antoine, et al.
Publicado: (2022)

RAB8, RAB10 and RILPL1 contribute to both LRRK2 kinase–mediated centrosomal cohesion and ciliogenesis deficits
por: Lara Ordónez, Antonio Jesús, et al.
Publicado: (2019)

Perspective on the current state of the LRRK2 field
por: Taymans, Jean-Marc, et al.
Publicado: (2023)

The small GTPase Rit2 modulates LRRK2 kinase activity, is required for lysosomal function and protects against alpha-synuclein neuropathology
por: Obergasteiger, Julia, et al.
Publicado: (2023)

LRRK2 phosphorylation status and kinase activity regulate (macro)autophagy in a Rab8a/Rab10-dependent manner
por: Kania, Elżbieta, et al.
Publicado: (2023)

Mind the Gap: LRRK2 Phenotypes in the Clinic vs. in Patient Cells
por: Goveas, Liesel, et al.
Publicado: (2021)

LRRK2 Kinase Inhibitor Rejuvenates Oxidative Stress-Induced Cellular Senescence in Neuronal Cells
por: Ho, Dong Hwan, et al.
Publicado: (2021)

Cellular processes associated with LRRK2 function and dysfunction
por: Wallings, Rebecca, et al.
Publicado: (2015)

Kinase inhibition of G2019S-LRRK2 enhances autolysosome formation and function to reduce endogenous alpha-synuclein intracellular inclusions
por: Obergasteiger, Julia, et al.
Publicado: (2020)

LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson’s Disease, Where Do We Stand?
por: Taymans, Jean-Marc, et al.
Publicado: (2016)

Centrosomal cohesion deficits as cellular biomarker in lymphoblastoid cell lines from LRRK2 Parkinson's disease patients
por: Fernández, Belén, et al.
Publicado: (2019)

‘Up with the LRRK’: a phosphorylated Rab10 assay for evaluation of LRRK2 activity and inhibitor engagement
por: Eyers, Patrick A.
Publicado: (2016)

Expression Analysis of Lrrk1, Lrrk2 and Lrrk2 Splice Variants in Mice
por: Giesert, Florian, et al.
Publicado: (2013)

LRRK2 and ubiquitination: implications for kinase inhibitor therapy
por: Melrose, Heather L.
Publicado: (2015)

Effects of LRRK2 Inhibitors on Nigrostriatal Dopaminergic Neurotransmission
por: Qin, Qi, et al.
Publicado: (2016)

Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease
por: Rosenbusch, Katharina E., et al.
Publicado: (2016)

Insights into the cellular consequences of LRRK2-mediated Rab protein phosphorylation
por: Fasiczka, Rachel, et al.
Publicado: (2023)

Role of LRRK2 in the regulation of dopamine receptor trafficking
por: Rassu, Mauro, et al.
Publicado: (2017)

Inhibitors of Leucine Rich Repeat Kinase 2 (LRRK2) Protect Against LRRK2-Models of Parkinson’s Disease
por: Lee, Byoung Dae, et al.
Publicado: (2010)

Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
por: Bright, Jessica M., et al.
Publicado: (2021)

Inhibitor treatment of peripheral mononuclear cells from Parkinson’s disease patients further validates LRRK2 dephosphorylation as a pharmacodynamic biomarker
por: Perera, G., et al.
Publicado: (2016)

Mutant LRRK2 exacerbates immune response and neurodegeneration in a chronic model of experimental colitis
por: Cabezudo, Diego, et al.
Publicado: (2023)

ATP13A2 Regulates Cellular α-Synuclein Multimerization, Membrane Association, and Externalization
por: Si, Jianmin, et al.
Publicado: (2021)

PPM1H phosphatase counteracts LRRK2 signaling by selectively dephosphorylating Rab proteins
por: Berndsen, Kerryn, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rq2v65rb9evalnn1gfi2suu297